Abstract:LB-367 Somatic mutations in the EGFR kinase are a cause of non-small cell lung cancer, and the presence of these mutations correlates with response to small-molecule tyrosine kinase inhibitors. Despite initial responses, longer-term efficacy of TKIs targeting the EGFR has been limited by the emergence of drug resistance, often conferred by an additional mutation of Threonine 790 in the EGFR to Methionine (T790M). This mutation, which lies in the ATP binding pocket of the kinase, confers resistance to anilinoquinazoline inhibitors including gefitinib and erlotinib. Importantly, the T790M mutant remains sensitive to a number of irreversible inhibitors, including HKI-272, Cl-387,785 and Cl-1033. These irreversible inhibitors are expected to bind in the ATP binding cleft in a manner analogous to similar reversible inhibitors, but they have an additional reactive group that forms a covalent bond with Cys 773 at the edge of the ATP binding cleft. The activity of these inhibitors against the T790M mutant therefore presents a paradox â\#8364;“ the steric effects of the T790M mutation that are presumed to underlie resistance to reversible anilinoquinazoline inhibitors should also interfere with the targeting of the irreversible inhibitors. To better understand the effects of the T790M mutant and the mechanism by which it confers resistance, we have determined the structure of this mutant alone and in complex with irreversible inhibitor HKI-272. Additionally, we have studied the kinetics and inhibitor-binding properties of the T790M mutant, the L858R/T790M double mutant, and the wild-type EGFR kinase. Surprisingly, using a direct binding assay we find that gefitinib binds to the T790M and L858R/T790M mutants with low nanomolar affinity (Kd=~5 nM), indicating that the T790M substitution does not sterically block gefitinib binding. These results are further supported by the crystal structure of HKI-272 in complex with the T790M mutant, which shows that the binding mode of HKI-272 is the same as that expected in the wild-type kinase. Kinetic analysis of the T790M mutant shows that it is approximately 5-fold more active that the wild-type kinase, with a similar Km for ATP. Interestingly, the L858R/T790M double mutant also has a Km for ATP equivalent to that of the wild-type kinase, whereas the L858R and G719S single mutants have markedly impaired affinity for ATP. Collectively, our findings indicate that much of the resistance induced by the T790M mutation may stem from its ability to restore wild-type affinity for ATP, rather than from its steric effects on inhibitor binding as was previously supposed. Since TKIs must compete with ATP to achieve their intended effect, their effective potency is diminished by the enhanced ATP-affinity. Irreversible inhibitors, as a class, overcome this effect through covalent binding.

Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase

Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation

Tumor Exome Sequencing and Copy Number Alterations Reveal Potential Predictors of Intrinsic Resistance to Multi-Targeted Tyrosine Kinase Inhibitors

Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6 H-pyrimido[5,4- b][1,4]oxazin-7(8 H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants

Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation

Design of novel anti-cancer drugs targeting TRKs inhibitors based 3D QSAR, molecular docking and molecular dynamics simulation

Design of New Second‐Generation TRK Inhibitors Targeting Tropomyosin Receptor Kinases by Using Molecular Docking, Molecular Dynamics Simulations and ADMET Properties

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases

Design, Synthesis and Evaluate of Indazolylaminoquinazoline Derivatives As Potent Tropomyosin Receptor Kinase (TRK) Inhibitors

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Combinatorial CRISPR screen reveals and as targets for synergistic drug combination for treating triple negative breast cancer

Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs

Roles of tropomyosin-related kinases in tumorigenesis and their small molecular inhibitors

EGFR kinase mutations in NSCLC: Unexpected structural and kinetic insights into the mechanism of the T790M resistance mutation and its inhibition by irreversible inhibitors including HKI-272